Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ampuero, Javier ^a   Ranchal, Isidora ^a   Nuñez, David ^a   Díaz Herrero, María del Mar ^b   Maraver, Marta ^a   Campo, José Antonio del ^a   Rojas, Ángela ^a   Camacho, Inés ^a   Figueruela, Blanca ^a   Bautista, Juan D ^b   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; GLUCAGON; GLUCOSE; GLUTAMINASE; GLUTAMINE; INSULIN; LEPTIN; METFORMIN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA FORMATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL STRAIN CACO 2; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; FOLLOW UP; GENE MUTATION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HORMONE BLOOD LEVEL; HUMAN; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUTAMINE CHALLENGE; PATIENT CODING; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGE FACTORS; AMMONIA; DIABETES COMPLICATIONS; ENZYME INHIBITORS; FEMALE; GLUTAMINASE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; METFORMIN; RETROSPECTIVE STUDIES; SEX FACTORS; SPAIN;

EID: 84869229224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049279     Document Type: Article

References (21)

1. Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J, (2001) Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96: 2718-23.
2. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, et al. (1999) Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 30: 890-5.
3. Romero-Gómez M, (2010) Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother 11: 1317-1327.
4. Romero-Gómez M, (2005) Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 20: 319-25.
5. Basu S, Zethelius B, Helmersson J, Berne C, Larsson A, et al. (2011) Cytokine-mediated inflammation is independently associated with insulin sensitivity measured by the euglycemic insulin clamp in a community-based cohort of elderly men. Int J ClinExp Med 4: 164-168.
6. Majid S, Azam Z, Shah HA, Salih M, Hamid S, et al. (2009) Factors determining the clinical outcome of acute variceal bleed in cirrhotic patients. Indian J Gastroenterol 28: 93-5.
7. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, et al. (2012) Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study. Am J Gastroenterol 107: 46-52.
8. Signal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E, (2006) Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 101: 1490-1496.
9. Lisa B, Wagner V, Rinella M, (2011) The role of insulin-sensitizing agents in the treatment of non alcoholic steatohepatitis. Ther Adv Gastroenterol 4: 249-263.
10. Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, et al. (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192: 233-42.
11. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G, (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30: 750-8.
12. American Diabetes Association (2006) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care; 29, Suppl1.
13. Sharma P, Sharma BC, (2010) Predictors of minimal hepatic encephalopathy in patients with cirrhosis. Saudi J Gastroenterol 16: 181-7.
14. Romero-Gómez M, Grande L, Camacho I, Benitez S, Irles JA, et al. (2002) Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J Hepatol 2002 37: 781-7.
15. Romero-Gómez M, Jover M, Del Campo JA, Royo JL, Hoyas E, et al. (2010) Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 153: 281-8.
16. Gundling F, Schmidtler F, Hapfelmeier A, Schulte B, Schmidt T, et al. (2011) Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int 31: 1406-1415.
17. Goldberg RB, (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94: 3171-82.
18. Jun DW, Kim KT, Lee OY, Chae JD, Son BK, et al. (2010) Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci 55: 1465-71.
19. Baglietto-Vargas D, Lopez-Tellez JF, Moreno-Gonzalez I, Gutierrez A, Aledo JC, (2004) Segregation of two glutaminase isoforms in islets of Langerhans. Biochem J 381: 483-7.
20. Watford M, Smith EM, Erbelding EJ, (1984) The regulation of phosphate-activated glutaminase activity and glutamine metabolism in the streptozotocin-diabetic rat. Biochem J 224: 207-14.
21. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, Muñoz-Noriega N, García-Morales LM, et al. (2012) The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab 25(1-2): 41-9.